Free Trial
NYSE:PFE

Pfizer (PFE) Stock Price, News & Analysis

$29.02
+0.12 (+0.42%)
(As of 08/21/2024 ET)
Today's Range
$28.93
$29.17
50-Day Range
$26.99
$31.38
52-Week Range
$25.20
$37.15
Volume
16.72 million shs
Average Volume
39.23 million shs
Market Capitalization
$164.42 billion
P/E Ratio
N/A
Dividend Yield
5.79%
Price Target
$34.54

Pfizer MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
19.0% Upside
$34.54 Price Target
Short Interest
Healthy
1.15% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.68
Upright™ Environmental Score
News Sentiment
0.51mentions of Pfizer in the last 14 days
Based on 36 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.22%
From $2.68 to $2.82 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.74 out of 5 stars

Medical Sector

46th out of 924 stocks

Pharmaceutical Preparations Industry

15th out of 426 stocks

PFE stock logo

About Pfizer Stock (NYSE:PFE)

Pfizer Inc. is a US-based multinational biotech company. The company operates as a research-based pharmaceutical company focused on the discovery, production and marketing of medicines and vaccines. It is the 2nd largest drugmaker globally by revenue and is ranked 64th on the Fortune 500 list. The company’s avenues of research include Immunology, Oncology, Cardiology, Endocrinology and Neurology.

Regarding its product line, the company has at least ten blockbuster drugs producing more than $1 billion in avenue revenue each. The company brought in over $81 billion in total revenue in 2021. The US is its main market and represents roughly 50% of all revenue. China and Japan make up roughly 12% of the business, while the rest come from the “rest of the world”. It employs roughly 79,000 people and is headquartered in New York state.

Pfizer Inc. was founded in 1849 by Charles Pfizer Sr. and his cousin Charles Earhart. The two were German immigrants and chemists that set up shops outside New York City to make medicinal compounds. The first major success was an antiparasitic called santonin, and the commercialization of citric acid-making technologies quickly followed that up. Their success with citric acid led to the company’s expansion and other major discoveries.

World War I caused a shortage of materials for making citric acid and forced the company to seek alternatives. The one they latched on to was the fermentation of certain fungi known to produce citric acid naturally. This led to the advancement of fermentation technology that was later used in the commercial production of penicillin and then the advancement of antibiotics in general.

Pfizer Inc was incorporated on June 2nd, 1942 in Delaware, and another period of expansion began. The postwar drop in demand for penicillin led to the discovery of newer, more marketable antibiotics and cemented the company’s role in modern medicine. By the time he 80s rolled around, the company was trading on the New York Stock Exchange and on the path to developing today’s blockbuster lineup.

The company’s top seller in 2021 was Comirnaty, a COVID-19 vaccine. It generated nearly $37 billion in 2021 and was followed by Prevnar, Ibrance and Eliquis with just over $5 billion in sales each. Other blockbuster names on Pfizer’s list include Xeljanz and Enbrel, each bringing in $3.5 billion. Pfizer operates 39 research and production facilities worldwide and sells its products in 125 countries.

As of 2022, the company had a robust pipeline of potential treatments, with more than 220 in some stage of clinical trials. Among its leading candidates is a vaccine for RSV, a life-threatening respiratory disease affecting children. 2021 highlights include 8 FDA approvals, four new regulatory submissions and 13 new trial startups. Pfizer is also a well-known dividend payer and has returned more than $8.7 billion to shareholders since going public.

 

PFE Stock Price History

PFE Stock News Headlines

house frame new construction
Value Investing: Unearthing 3 Hidden Gems in Today's Market (PFE)
Discover undervalued companies and build long-term wealth through the insightful strategy of value investing.
In this photo The logo of Merck and Co, Inc.Merck is an American multinational pharmaceutical company
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why (PFE)
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
This Crypto Is Set to Explode in August
With the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the latest DeFi craze or the next hot meme coin, the savviest investors are quietly positioning themselves for a different kind of explosion. This year's Bitcoin halving bull run is about to unleash a tidal wave in a completely undervalued sector of the crypto market.
syringe and vaccine in hand
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze? (PFE)
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
(AP Illustration/Jenni Sohn)
Pfizer CEO on moving beyond COVID vaccines to become a leader in cancer and obesity treatments
Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world
Novavax stock price forecast
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp? (PFE)
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
A soldier walks past crosses and flags at an US cemetery near Colleville-sur-Mer Normandy, Thursday…
About half of US state AGs went on France trip sponsored by group with lobbyist and corporate funds
About half the U.S. state attorneys general have traveled to France for an event cosponsored by a group largely funded by companies
The Pfizer logo is displayed at the company's headquarters on February 5, 2021, in New York
Drugmaker Pfizer hikes 2024 forecast again after initially underwhelming Wall Street
Pfizer now expects 2024 earnings to wind up well above analyst expectations after starting the year with a forecast that disappointed Wall Street
This Crypto Is Set to Explode in August
With the 2024 Bitcoin Halving, there's a potential HUGE bull run for altcoins. While everyone's chasing the latest DeFi craze or the next hot meme coin, the savviest investors are quietly positioning themselves for a different kind of explosion. This year's Bitcoin halving bull run is about to unleash a tidal wave in a completely undervalued sector of the crypto market.
Healthcare business, Medical business data growth chart. Doctor working on network with professional service, Research and development, Business investment, Medical technology and health service.
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
The healthcare sector, represented by the XLV ETF, has seen a resurgence, breaking out of a multi-year consolidation phase and surging almost 3% in July.
Pfizer (NYSE:PFE) Stock Rating Reaffirmed by Cantor Fitzgerald
Was Q2 The Turning Point For Pfizer Stock?
Time To Buy These 3 Extremely Undervalued Stocks
Pfizer Is Staking Its Turnaround on Cancer Drugs
See More Headlines
Receive PFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pfizer and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 6/14 Dividend
5/09/2024
Dividend Payable
6/14/2024
Ex-Dividend for 9/3 Dividend
7/26/2024
Last Earnings
7/30/2024
Today
8/22/2024
Dividend Payable
9/03/2024
Next Earnings (Estimated)
10/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
71708110
Employees
88,000
Year Founded
1849

Price Target and Rating

Average Stock Price Target
$34.54
High Stock Price Target
$45.00
Low Stock Price Target
$29.00
Potential Upside/Downside
+19.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

Net Income
$2.12 billion
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$55.17 billion
Cash Flow
$2.99 per share
Book Value
$15.52 per share

Miscellaneous

Outstanding Shares
5,666,593,000
Free Float
5,663,193,000
Market Cap
$164.42 billion
Optionable
Optionable
Beta
0.69

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Pfizer Stock? PFE Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer's recent quarterly earnings per share of $0.60 exceeded analysts' estimates by $0.14, indicating strong financial performance.
  • The company's positive return on equity of 8.31% showcases efficient utilization of shareholder funds to generate profits.
  • Pfizer's revenue growth of 2.1% year-over-year demonstrates a stable and growing business operation.
  • The quarterly dividend of $0.42 per share with an annualized dividend yield of 5.73% provides investors with a steady income stream.
  • Institutional investors holding 68.36% of Pfizer's stock can indicate confidence in the company's future prospects.

Cons

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Pfizer's negative net margin of 4.66% suggests challenges in controlling costs and maximizing profitability.
  • The company's dividend payout ratio of -2,800.00% raises concerns about the sustainability of the dividend payments.
  • Fluctuations in the biopharmaceutical industry, regulatory changes, and patent expirations can impact Pfizer's future revenue and earnings.
  • Market competition and the need for continuous innovation to maintain market share pose risks to Pfizer's long-term growth.
  • Investors should consider the current stock price and evaluate if it aligns with the company's financial performance and growth potential.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, August 19, 2024. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

PFE Stock Analysis - Frequently Asked Questions

How have PFE shares performed this year?

Pfizer's stock was trading at $28.79 at the beginning of 2024. Since then, PFE shares have increased by 0.8% and is now trading at $29.0150.
View the best growth stocks for 2024 here
.

How were Pfizer's earnings last quarter?

Pfizer Inc. (NYSE:PFE) released its earnings results on Tuesday, July, 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.14. The firm's revenue for the quarter was up 2.1% compared to the same quarter last year.
Read the conference call transcript
.

What is Albert Bourla's approval rating as Pfizer's CEO?

358 employees have rated Pfizer Chief Executive Officer Albert Bourla on Glassdoor.com. Albert Bourla has an approval rating of 92% among the company's employees. This puts Albert Bourla in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Does Pfizer have any subsidiaries?

Pfizer subsidiaries include these companies: ReViral, Arena, Trillium Therapeutics, Amplyx Pharmaceuticals, Array BioPharma, Therachon, Medivation, and more.

Who are Pfizer's major shareholders?

Top institutional investors of Pfizer include Massachusetts Financial Services Co. MA (1.27%), Legal & General Group Plc (0.82%), Bank of New York Mellon Corp (0.74%) and Dimensional Fund Advisors LP (0.59%). Insiders that own company stock include Pfizer Inc, William R Carapezzi Jr, Jennifer B Damico, Scott Gottlieb, Alexander R Mackenzie, John D Young and Douglas M Lankler.
View institutional ownership trends
.

How do I buy shares of Pfizer?

Shares of PFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Pfizer own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pfizer investors own include AT&T (T), Johnson & Johnson (JNJ), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), AbbVie (ABBV) and Walt Disney (DIS).

This page (NYSE:PFE) was last updated on 8/22/2024 by MarketBeat.com Staff

From Our Partners